SCHEMBL12379038

SCHEMBL12379038

Cc1ccc(N(c2ccc(-c3ccccc3)cc2)c2cc(-c3ccc4c(c3)C(C)(C)c3cc(C(C)(C)C)ccc3-4)cc(-c3ccc4c(c3)C(C)(C)c3cc(C(C)(C)C)ccc3-4)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
PDK2 Q15119 3/20 0.39
DHODH Q02127 2/20 0.33
PGR P06401 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
HPRT1 P00492 1/20 0.32
DHFR P00374 2/20 0.31
PTPN5 P54829 1/20 0.30
TSHR P16473 1/20 0.30
PTGES O14684 1/20 0.30
ALOX5 P09917 1/20 0.30
NPC1 O15118 1/20 0.30
PLA2G1B P04054 1/20 0.30
NFKB1 P19838 1/20 0.30
CASP3 P42574 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12379022 0.97 PDK2 (0.38) ALDH1A1MAPTPDK2TSHRNPC1
SCHEMBL12379031 0.95 PDK2 (0.36) ALDH1A1MAPTPDK2DHODHRXRA
SCHEMBL12379050 0.94 DHODH (0.37) ALDH1A1MAPTPDK2DHODHRXRA
SCHEMBL12379045 0.94 DHODH (0.37) ALDH1A1MAPTPDK2DHODHRXRA
SCHEMBL12379035 0.94 PDK2 (0.36) ALDH1A1MAPTPDK2DHODHRXRA
SCHEMBL12379056 0.94 MAPT (0.38) ALDH1A1MAPTPDK2DHODHTSHR
SCHEMBL12568847 0.94 MAPT (0.37) ALDH1A1MAPTPDK2TSHR
SCHEMBL12379018 0.93 MAPT (0.37) ALDH1A1MAPTPDK2TSHR
SCHEMBL12379026 0.92 PDK2 (0.34) ALDH1A1MAPTPDK2DHODH
SCHEMBL12379048 0.92 DHODH (0.34) ALDH1A1MAPTPDK2DHODHRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288018-B2 Amino compound for organic light-emitting device and organic light-emitting device including the same CANON KABUSHIKI KAISHA (JP) 2012-10-16 US disclosed
US-8288018-B2 Amino compound for organic light-emitting device and organic light-emitting device including the same CANON KABUSHIKI KAISHA (JP) 2012-10-16 US disclosed
US-20110198576-A1 AMINO COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CANON KABUSHIKI KAISHA (JP) 2011-08-18 US disclosed
US-20110198576-A1 AMINO COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CANON KABUSHIKI KAISHA (JP) 2011-08-18 US disclosed
US-7960039-B2 Amino compound for organic light-emitting device and organic light-emitting device including the same CANON KABUSHIKI KAISHA (JP) 2011-06-14 US disclosed
US-7960039-B2 Amino compound for organic light-emitting device and organic light-emitting device including the same CANON KABUSHIKI KAISHA (JP) 2011-06-14 US disclosed
US-20070228941-A1 AMINO COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CANON KABUSHIKI KAISHA (JP) 2007-10-04 US disclosed
US-20070228941-A1 AMINO COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CANON KABUSHIKI KAISHA (JP) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070228941-A1 AMINO COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME ARL1, APOL1, UFL1 ALDH1A1 606/4885MAPT 2978/4885PDK2 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.